🎉We won! Proud to announce that Recursion has won a @FiercePharma AI Innovation Award for AI Innovation in Drug Discovery. 💠 The award recognizes the impact of the Recursion OS which connects biology, design, and clinical development into a single AI product engine. They note that this engine is more than a collection of point solutions. “Instead of stitching together fragmented public datasets, Recursion generates its own proprietary data at industrial scale and feeds it directly back into the system.” As CEO Najat Khan says: “It enables our scientists to generate and test hypotheses at a scale and resolution that simply wasn’t possible before, uncovering novel biology and designing more precise medicines faster for patients who are waiting. And it has delivered tangible proof points – including multiple drugs advancing in our internal clinical and pre-clinical pipeline, and ongoing milestones for pharma partners.” Those proof points include REC-4881 for FAP (familial adenomatous polyposis). “REC-4881 marks the first potential treatment for the condition and the first clinical validation of the Recursion OS, backed by encouraging Phase 2 data,” they write. “The same platform also uncovered a novel mechanism for treating FAP – MEK 1/2 inhibition – and used real-world data to broaden patient eligibility for the trial.”  We’ll be presenting additional Phase 2 data from the TUPELO trial at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting in November. 🚀 We’re thrilled to have won this recognition from Fierce and look forward to continuing to demonstrate proof points from both partnerships and clinical programs. 👉 Read more: fiercepharma.com/ai-and-mach… #FierceAIInnovationAwards